跳转至内容
Merck
CN
所有图片(3)

文件

AB9986

Sigma-Aldrich

抗磷酸化BRCA2(Ser3291)抗体

from rabbit, purified by affinity chromatography

别名:

BRCA1/BRCA2-containing complex, subunit 2, Fanconi anemia group D1 protein 3, Fanconi anemia, complementation group D1, breast and ovarian cancer susceptibility gene, early onset, breast cancer 2 tumor suppressor, breast cancer 2, early onset, breast can

登录查看公司和协议定价


About This Item

UNSPSC代码:
12352203
eCl@ss:
32160702
NACRES:
NA.41

生物来源

rabbit

质量水平

抗体形式

affinity purified immunoglobulin

抗体产品类型

primary antibodies

克隆

polyclonal

纯化方式

affinity chromatography

种属反应性

rhesus macaque, horse, human

种属反应性(根据同源性预测)

rat (based on 100% sequence homology), mouse (based on 100% sequence homology), hamster (based on 100% sequence homology), cat (based on 100% sequence homology), equine (based on 100% sequence homology), canine (based on 100% sequence homology), chimpanzee (based on 100% sequence homology), rhesus monkey (based on 100% sequence homology)

技术

dot blot: suitable
immunocytochemistry: suitable
immunohistochemistry: suitable

NCBI登记号

UniProt登记号

运输

wet ice

靶向翻译后修饰

phosphorylation (pSer3291)

基因信息

human ... BRCA2(675)

一般描述

BRCA2 (乳腺癌2型易感蛋白)是一种由BRCA2基因编码的肿瘤抑制蛋白(tumor suppressor protein )。
该基因编码的蛋白在无错式双链断裂修复(error-free double-strand break repair)和同源重组中起直接作用。BRCA2 类似于肿瘤抑制基因BRCA1。BRCA2以及BRCA1 的遗传突变与增加的乳腺或卵巢癌患病风险有关。尽管RCA1 和BRCA2基因的结构差别很大,它们有一些类似的功能。两种基因产生的蛋白对受损DNA的修复必不可少,并且与RAD51基因产生的蛋白相互作用。这三种蛋白一起在维持人类基因组的稳定性方面起一定作用,并且防止出现可导致癌症的危险基因重排。

特异性

该抗体识别Ser3291周围内部结构域上及其周围的磷酸化人 BRCA2。

免疫原

KLH 偶联的线性肽,对应于Ser3291周围内部结构域上及其周围磷酸化的人 BRCA2。
表位:Ser3291周围的内部结构域

应用

免疫细胞化学分析: 一个先前批次的1:500稀释液在MCF-7细胞中检测到BRCA2。

免疫组化分析: 一个先前批次的1:100稀释液在转移性导管癌组织中检测到BRCA2。
抗磷酸化BRCA2(Ser3291)抗体是一种兔多克隆抗体,可用于检测磷酸化BRCA2(Ser3291),也称含BRCA1/BRCA2复合物亚基2&范科尼贫血组D1蛋白3, 已在 ICC、IHC、DB中进行了验证。
研究子类别
细胞周期,DNA 复制&修复

肿瘤蛋白

质量

通过斑点印迹法对磷酸化和非磷酸化BRCA2的修饰和未修饰肽进行评估。

斑点印迹分析: 2 µg/mL该抗体在磷酸化和非磷酸化BRCA2的修饰和未修饰肽中检测到BRCA2。

目标描述

约390 kDa

分析说明

对照
磷酸化和非磷酸化BRCA2的修饰和未修饰肽

其他说明

浓度:请参考批次特异性浓缩物的检验报告。

Not finding the right product?  

Try our 产品选型工具.

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Lifeng Chen et al.
Clinical and translational medicine, 11(3), e341-e341 (2021-03-31)
PARP inhibitors induce DNA lesions, the repair of which are highly dependent on homologous recombination (HR), and preferentially kill HR- deficient cancers. However, cancer cells have developed several mechanisms to transform HR and confer drug resistance to PARP inhibition. Therefore
Sissel Hauge et al.
Oncotarget, 8(7), 10966-10979 (2016-12-29)
Recent studies have shown synergistic cytotoxic effects of simultaneous Chk1- and Wee1-inhibition. However, the mechanisms behind this synergy are not known. Here, we present a flow cytometry-based screen for compounds that cause increased DNA damage in S-phase when combined with
Fang Zhang et al.
Cell reports, 32(4), 107974-107974 (2020-07-30)
Attenuated DNA repair leads to genomic instability and tumorigenesis. BRCA1/BARD1 are the best-known tumor suppressors that promote homology recombination (HR) and arrest cell cycle. However, it remains ambiguous whether and how their E3 ligase activity regulates HR. Here, we demonstrate
Gro Elise Rødland et al.
Frontiers in oncology, 9, 1301-1301 (2019-12-19)
The CD37 targeting radioimmunoconjugate 177Lu-lilotomab satetraxetan (Betalutin) is currently being evaluated in a clinical phase 2b trial for patients with follicular lymphoma (FL) and in a phase 1 trial for patients with diffuse large B-cell lymphoma (DLBCL). Herein we have
Gro Elise Rødland et al.
Cancers, 13(15) (2021-08-08)
Inhibitors of WEE1 and ATR kinases are considered promising for cancer treatment, either as monotherapy or in combination with chemo- or radiotherapy. Here, we addressed whether simultaneous inhibition of WEE1 and ATR might be advantageous. Effects of the WEE1 inhibitor

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门